ITGR

Business Context and Reporting Period

Company: Wilson Greatbatch Technologies, Inc. (Note: Input metadata referenced "Integer Holdings Corp," but the filing text identifies the registrant as Wilson Greatbatch Technologies, Inc.)
Filing Type: Form 10-K Annual Report
Reporting Period: Fiscal year ended January 3, 2003 (53-week year)
Business Overview: A leading developer and manufacturer of batteries, capacitors, feedthroughs, enclosures, and other components for implantable medical devices (pacemakers, ICDs) and commercial power sources for oil and gas exploration, aerospace, and oceanographic equipment.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenues increased 23% to $167.3 million, driven by a 32% increase in Medical Technology segment revenues ($141.9 million) and the inclusion of the Greatbatch-Globe acquisition (enclosures) in the second half of 2002.
• Segment Performance:
  • Medical Batteries: ICD battery revenues grew 28% due to increased demand; Pacemaker battery revenues declined 11%.
  • Components: Revenues surged 61% to $65.3 million, primarily due to the full-year inclusion of Greatbatch-Sierra (EMI filters) and Greatbatch-Globe.
  • Commercial Power Sources: Revenues decreased 9% to $25.4 million due to reduced oil and gas exploration activity in the first half of 2002.
• Profitability: Net income increased 70% to $14.4 million. Gross margin compressed from 45% to 42% due to production yield issues at Greatbatch-Sierra, reduced royalty revenues, and the inclusion of lower-margin operations from the Globe acquisition.
• Accounting Changes: Adoption of SFAS No. 142 eliminated goodwill amortization, significantly reducing intangible amortization expenses from $7.7 million in 2001 to $3.7 million in 2002.
• Debt Structure: Long-term debt increased to $77.0 million following an amendment to the credit facility to $120 million to finance the Globe acquisition.

Guidance, Outlook, Risks, and Unusual Items

• Outlook: Management anticipates higher capital spending in 2003 for a new medical battery manufacturing factory and IT infrastructure. The company expects continued growth in the implantable medical device industry, particularly for ICDs.
• Unusual Items:
  • Write-offs: Recorded a $1.7 million non-recurring charge for the write-off of a noncompete agreement following the death of Mr. Fred Hittman. Recorded a $1.5 million write-off of an investment in an unrelated company.
  • Extraordinary Loss: No extraordinary loss in 2002; 2001 included a $3.0 million loss related to debt restructuring.
• Risks and Contingencies:
  • Customer Concentration: Two customers (Guidant and St. Jude Medical) accounted for approximately 66% of medical technology revenues in 2002.
  • Intellectual Property: Reliance on a license from Evans Capacitor Company for wet tantalum capacitor technology; cancellation would seriously impair production capabilities.
  • Supply Chain: Dependence on a limited number of suppliers for critical raw materials.

Investor Verification Checklist

• Customer Concentration: Verify the stability of supply agreements with Guidant (expires 2004) and St. Jude Medical (expires 2003) given they represent two-thirds of medical revenue.
• Acquisition Integration: Assess the integration progress and margin performance of the Greatbatch-Globe and Greatbatch-Sierra acquisitions, which drove revenue growth but pressured gross margins.
• Patent Expirations: Monitor the impact of expiring patents on royalty revenues, which dropped to zero in 2002.
• Commercial Market Volatility: Evaluate exposure to the cyclical oil and gas exploration market, which caused a decline in commercial power source revenues.
• Debt Covenants: Review compliance with EBITDA and leverage covenants under the $120 million credit facility.